scholarly journals Manufacturing of Fermented dairy products by using Lactobacillus casei which had the ability to lower cholesterol

2010 ◽  
Vol 4 (1) ◽  
pp. 72-81
Author(s):  
Abdul Wahed Baker ◽  
Zaid A. A. ◽  
Amer A. A.

The study included manufacturing of fermented dairy products by using full cream milk of four kinds of mammalian: (Buffalos, Cows, Sheep's and Goats); with the use of Lactobacillus casei as a starter for the production of fermented dairy products which had the ability to lower cholesterol percentage in the above mentioned products by (71.4, 70, 74.8 and 67.7)% respectively. The viability of Lb. casei had not been affected significantly during storage shelf life of 21days " The product shelf life " , keeping their therapeutic properties unaltered with high viable number of bacteria at time of consumption. The viable counts of the bacteria after storage period for manufactured products were (1.06× 109, 8.1× 108, 7.5× 108and 8× 108) CFU/ml respectively. These numbers represent a decrease equal to one logarithmic cycle for each of manufactured products of Cows, Sheep's and Goats milk, and the decrease of bacteria's viability of manufactured products of Buffalos milk was less than one logarithmic cycle. Results of statistical analysis showed that there was highly significant differences (P<0.05) in the viable bacterial cells counts between manufactured products. By sensory comparison of the manufactured fermented products together, the results shows that the manufactured products from Buffalos milk was the best then the manufactured products of Cows milk then Sheep's milk then goats milk

2017 ◽  
Vol 6 (2) ◽  
pp. 75 ◽  
Author(s):  
Moawiya A. Haddad

Objectives: The study aimed to measure the viability of probiotic bacteria in different probiotic fermented dairy products marketed in Jordan during their shelf lives. Methods: Ten products which were all known commercial probiotic fermented dairy drinks were purchased from main market stores at 0 day of processing, and kept under 4oC for the assigned time intervals (1, 7, 14 day). These products included 7 stirred yogurt Activia, Activia low-fat, Actimel, Baladna, Acti-Yogho, Moffedo, and Vital, and 2 set yogurt (Activia - apricot and peach, Activia light – strawberry) and one stirred yogurt (Activia- stirred). Samples were tested for probiotic count at those intervals in an unopened refrigerated bottles. Sensory evaluation using hedonic scale was carried out on the above products in an unopened package at the same indicated intervals. Morphology of probiotic bacteria in commercial products was also confirmed microscopically.Results: The results of the viability of probiotic counts in log10 remaining above 7 log until the end of shelf life (14 d) except for four products including Moffedo, vital, Activia set yogurt light – strawberry, and Activia (stirred yogurt) which decreased to 3.4, 4.9, 5.0, and 5.0 respectively at the end storage period. The pH for all products until the end of the study were between 4.1- 4.5. The best average of all sensory characteristics using hedonic scale (8.3) was for Actimel, whereas the lowest (7.1) was for both Moffedo and Activia set yogurt- Apricot and peach.Conclusion: The counts of probiotic bacteria in fermented dairy products is not always above the therapeutic dose of 6.0 log cfu/g, which urge governmental authorities to establish a standard related to these products.


2018 ◽  
Vol 200 (7) ◽  
pp. 1111-1121 ◽  
Author(s):  
Jing Feng ◽  
Yujun Jiang ◽  
Mingyu Li ◽  
Siyu Zhao ◽  
Yanming Zhang ◽  
...  

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Kamil Rashidi ◽  
Bahman Razi ◽  
Mina Darand ◽  
Azadeh Dehghani ◽  
Parisa Janmohammadi ◽  
...  

Abstract Background Previous studies have suggested that the consumption of probiotic fermented dairy products (PFDP) may have a protective effect on respiratory tract infections (RTIs). However, the results of studies are inconclusive. We aimed to systematically investigate the effect of PFDP on RTIs by performing a meta-analysis of randomized controlled trials (RCTs). Methods PubMed and Scopus databases were systematically searched up to October 2020 to identify eligible RCTs. Meta-analysis outcomes were risk of incidence of upper (URTIs ) and lower (LRTIs ) respiratory tract infections. A random-effects model was used to pool the relative risks (RR) and corresponding 95 % confidence intervals (CI) for outcomes following conception of PFDP. Results A total of 22 RCTs, with a total sample size of 10,190 participants, were included in this meta-analysis. Compared with placebo, consumption of PFDP had a significant protective effect against RTIs in the overall analysis (RR = 0.81, 95 %CI: 0.74 to 0.89) and in children (RR = 0.82, 95 %CI: 0.73 to 0.93), adults (RR = 0.81, 95 %CI: 0.66 to 1.00), and elderly population (RR = 0.78, 95 %CI: 0.61 to 0.98). The significant decreased risk of RTIs was also observed for URTIs (RR = 0.83, 95 %CI: 0.73 to 0.93), while, this effect was marginal for LRTIs (RR = 0.78, 95 %CI: 0.60 to 1.01, P = 0.06). The disease-specific analysis showed that PFDP have a protective effect on pneumonia (RR = 0.76, 95 %CI: 0.61 to 0.95) and common cold (RR = 0.68, 95 %CI: 0.49 to 0.96). Conclusions Consumption of PFDP is a potential dietary approach for the prevention of RTIs.


Sign in / Sign up

Export Citation Format

Share Document